New strategies in the management of leptomeningeal metastases.
The management of patients with leptomeningeal metastases (LM) is multifaceted and complex. Even with an aggressive approach, therapeutic outcomes are uniformly disappointing. This is because of the relentless growth of the central nervous system (CNS) and/or the systemic cancers, or their lethal complications. Advances in the understanding of the homing of cancer cells to the CNS, and of cancer metastasis in general, and more effective anticancer drugs that are adequately delivered to the CNS and cerebrospinal fluid (CSF) are needed to improve outcomes for patients with LM. These advances may lead to better treatments for this disease and, ultimately, its prevention.
Groves
Morris D
MD
UT MD Anderson Cancer Center, Department of Neuro-Oncology, 1400 Holcombe Blvd, Unit 431, Houston, TX 77030, USA. mgroves@mdanderson.org
D000971:Antineoplastic Combined Chemotherapy Protocols; D016503:Drug Delivery Systems; D006801:Humans; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000556:secondary*